Edition:
United States

Torii Pharmaceutical Co Ltd (4551.T)

4551.T on Tokyo Stock Exchange

2,961JPY
24 Mar 2017
Change (% chg)

¥13 (+0.44%)
Prev Close
¥2,948
Open
¥2,955
Day's High
¥2,964
Day's Low
¥2,918
Volume
29,600
Avg. Vol
39,263
52-wk High
¥3,050
52-wk Low
¥1,981

Latest Key Developments (Source: Significant Developments)

Menlo Therapeutics signs license agreement with Japan Tobacco, Torii Pharma for NK-1 receptor antagonist
Wednesday, 10 Aug 2016 01:00pm EDT 

Menlo Therapeutics Inc : Menlo Therapeutics signs exclusive license agreement with Japan Tobacco and Torii Pharmaceuticals for development and commercialization of NK-1 receptor antagonist in Japan . Entered into license agreement with Japan Tobacco Inc. and Torii Pharmaceutical for development,commercialization of serlopitant in Japan .JT,Torii to pay co upfront licensing fees,payments upon achievement of certain milestones, royalties based on future sales in Japan.  Full Article

Torii Pharmaceutical raises consolidated full-year outlook for FY 2015
Monday, 18 Jan 2016 01:00am EST 

Torii Pharmaceutical Co Ltd:Says the company increased the consolidated full-year outlook for revenue to 62,370 mln yen from 61,300 mln yen, for the fiscal year ending Dec. 31, 2015.Operating profit forecast increased to 4,910 mln yen from 4,000 mln yen.Ordinary profit forecast increased to 5,130 mln yen from 4,200 mln yen.Net profit forecast increased to 3,520 mln yen from 2,600 mln yen.Earnings per share increased to 124.38 yen from 91.87 yen.Comments the increased sales of core products and cost control are the main reasons for the forecast.  Full Article

Torii Pharmaceutical files New Drug Application for TO-206
Friday, 25 Dec 2015 03:00am EST 

Torii Pharmaceutical Co Ltd:Filed a New Drug Application for TO-206, an allergen immunotherapy tablet for Japanese cedar pollinosis to the Japanese Ministry of Health, Labour and Welfare.  Full Article

Torii Pharmaceutical announces new drug approval in Japan
Monday, 28 Sep 2015 03:00am EDT 

Torii Pharmaceutical Co Ltd:Obtained the marketing approval of MITICURE® House Dust Mite Sublingual Tablets (“MITICURE” hereinafter), an allergen immunotherapy tablet for house dust mite allergy, for the indication of allergic rhinitis. in Japan.  Full Article

More From Around the Web